Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
Aphakia, Postcataract
About this trial
This is an interventional treatment trial for Aphakia, Postcataract
Eligibility Criteria
Inclusion Criteria: Adult patients with bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing bilateral sequential implantation within 21 days using Clareon Vivity and Clareon Vivity Torics IOL powers between +10D to +30.0D, T3-T6 Potential acuity measured post-operatively 20/25 or better in both eyes Exclusion Criteria: History of ocular or refractive surgery Ocular or systemic comorbidities that may alter or reduce visual acuity, contrast sensitivity, binocularity, or impair reading performance such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc. Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity Intraoperative or postoperative complications
Sites / Locations
- Palo Alto Medical FoundationRecruiting
Arms of the Study
Arm 1
Experimental
Mini-Monovision Arm
Bilateral implantation of Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision.